# Angiodynamics Inc: financial statements, quarterly

ANGO · Nasdaq · CIK 1275187 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/ango.md) · [Financials](/companies/ango/financials.md) · [Filings](/companies/ango/filings.md) · [Insiders](/companies/ango/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ango/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [79.1](/filings/0001275187-25-000005.md) | [75.2](/filings/0001275187-25-000010.md) | [71.0 d](/filings/0001628280-26-048138.md) | [67.5](/filings/0001628280-25-043689.md) | [72.8](/filings/0001275187-26-000003.md) | [72.0](/filings/0001628280-26-023008.md) | [80.2 d](/filings/0001628280-26-048138.md) | [75.7](/filings/0001628280-26-065423.md) | [79.4](/filings/0001275187-26-000003.md) | [78.4](/filings/0001628280-26-023008.md) | [86.6 d](/filings/0001628280-26-048138.md) | [80.9](/filings/0001628280-26-065423.md) |
| Cost of revenue | $m | [38.8](/filings/0001275187-25-000005.md) | [39.3](/filings/0001275187-25-000010.md) | [32.5 d](/filings/0001628280-26-048138.md) | [30.8](/filings/0001628280-25-043689.md) | [32.9](/filings/0001275187-26-000003.md) | [33.1](/filings/0001628280-26-023008.md) | [37.9 d](/filings/0001628280-26-048138.md) | [33.9](/filings/0001628280-26-065423.md) | [34.7](/filings/0001275187-26-000003.md) | [36.9](/filings/0001628280-26-023008.md) | [39.8 d](/filings/0001628280-26-048138.md) | [32.9](/filings/0001628280-26-065423.md) |
| Gross profit | $m | [40.3](/filings/0001275187-25-000005.md) | [35.9](/filings/0001275187-25-000010.md) | [38.5 d](/filings/0001628280-26-048138.md) | [36.7](/filings/0001628280-25-043689.md) | [39.9](/filings/0001275187-26-000003.md) | [38.9](/filings/0001628280-26-023008.md) | [42.2 d](/filings/0001628280-26-048138.md) | [41.9](/filings/0001628280-26-065423.md) | [44.8](/filings/0001275187-26-000003.md) | [41.5](/filings/0001628280-26-023008.md) | [46.8 d](/filings/0001628280-26-048138.md) | [48.0](/filings/0001628280-26-065423.md) |
| Research and development | $m | [8.7](/filings/0001275187-25-000005.md) | [8.2](/filings/0001275187-25-000010.md) | [6.7 d](/filings/0001628280-26-048138.md) | [6.3](/filings/0001628280-25-043689.md) | [6.4](/filings/0001275187-26-000003.md) | [6.9](/filings/0001628280-26-023008.md) | [6.6 d](/filings/0001628280-26-048138.md) | [6.4](/filings/0001628280-26-065423.md) | [7.8](/filings/0001275187-26-000003.md) | [7.1](/filings/0001628280-26-023008.md) | [8.2 d](/filings/0001628280-26-048138.md) | [8.0](/filings/0001628280-26-065423.md) |
| Operating income | $m | [(13.1)](/filings/0001275187-25-000005.md) | [(200)](/filings/0001275187-25-000010.md) | [(14.4) d](/filings/0001628280-26-048138.md) | [(13.1)](/filings/0001628280-25-043689.md) | [(11.1)](/filings/0001275187-26-000003.md) | [(10.0)](/filings/0001628280-26-023008.md) | [(5.8) d](/filings/0001628280-26-048138.md) | [(10.7)](/filings/0001628280-26-065423.md) | [(6.1)](/filings/0001275187-26-000003.md) | [(13.0)](/filings/0001628280-26-023008.md) | [(10.2) d](/filings/0001628280-26-048138.md) | [(7.3)](/filings/0001628280-26-065423.md) |
| Interest expense | $m | [(0.5)](/filings/0001628280-24-000857.md) | [(0.4)](/filings/0001628280-24-015487.md) | [(0.6) d](/filings/0001628280-24-032989.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [16.4](/filings/0001275187-25-000005.md) | [(12.0)](/filings/0001275187-25-000010.md) | [(0.7) d](/filings/0001628280-26-048138.md) | [0.1](/filings/0001628280-25-043689.md) | [(0.1)](/filings/0001275187-26-000003.md) | [(0.0)](/filings/0001628280-26-023008.md) | [(0.1) d](/filings/0001628280-26-048138.md) | [0.1](/filings/0001628280-26-065423.md) | [(0.0)](/filings/0001275187-26-000003.md) | [0.0](/filings/0001628280-26-023008.md) | [0.4 d](/filings/0001628280-26-048138.md) | [(0.2)](/filings/0001628280-26-065423.md) |
| Net income | $m | [(29.0)](/filings/0001275187-25-000010.md) | [(188)](/filings/0001275187-25-000010.md) | [(13.5) d](/filings/0001140361-26-037995.md) | [(12.8)](/filings/0001628280-26-023008.md) | [(10.7)](/filings/0001628280-26-023008.md) | [(4.4)](/filings/0001628280-26-023008.md) | [(6.1) d](/filings/0001140361-26-037995.md) | [(10.9)](/filings/0001628280-26-065423.md) | [(6.4)](/filings/0001628280-26-023008.md) | [(8.1)](/filings/0001628280-26-023008.md) | [(11.4) d](/filings/0001140361-26-037995.md) | [(7.1)](/filings/0001628280-26-065423.md) |
| Diluted EPS | $ per share | [(0.72)](/filings/0001275187-25-000005.md) | [(4.67)](/filings/0001275187-25-000010.md) | not reported | [(0.31)](/filings/0001628280-25-043689.md) | [(0.26)](/filings/0001275187-26-000003.md) | [(0.11)](/filings/0001628280-26-023008.md) | not reported | [(0.26)](/filings/0001628280-26-065423.md) | [(0.15)](/filings/0001275187-26-000003.md) | [(0.19)](/filings/0001628280-26-023008.md) | not reported | [(0.17)](/filings/0001628280-26-065423.md) |
| Basic EPS | $ per share | [(0.72)](/filings/0001275187-25-000005.md) | [(4.67)](/filings/0001275187-25-000010.md) | not reported | [(0.31)](/filings/0001628280-25-043689.md) | [(0.26)](/filings/0001275187-26-000003.md) | [(0.11)](/filings/0001628280-26-023008.md) | not reported | [(0.26)](/filings/0001628280-26-065423.md) | [(0.15)](/filings/0001275187-26-000003.md) | [(0.19)](/filings/0001628280-26-023008.md) | not reported | [(0.17)](/filings/0001628280-26-065423.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [60.9](/filings/0001628280-24-000857.md) | [78.5](/filings/0001628280-24-015487.md) | [76.1](/filings/0001275187-25-000014.md) | [55.0](/filings/0001628280-24-042176.md) | [54.1](/filings/0001275187-25-000005.md) | [44.8](/filings/0001275187-25-000010.md) | [55.9](/filings/0001628280-26-048138.md) | [38.8](/filings/0001628280-25-043689.md) | [41.6](/filings/0001275187-26-000003.md) | [37.8](/filings/0001628280-26-023008.md) | [53.9](/filings/0001628280-26-065423.md) | [34.0](/filings/0001628280-26-065423.md) |
| Current assets | $m | [185](/filings/0001628280-24-000857.md) | [197](/filings/0001628280-24-015487.md) | [193](/filings/0001275187-25-000014.md) | [173](/filings/0001628280-24-042176.md) | [175](/filings/0001275187-25-000005.md) | [172](/filings/0001275187-25-000010.md) | [168](/filings/0001628280-26-048138.md) | [157](/filings/0001628280-25-043689.md) | [161](/filings/0001275187-26-000003.md) | [156](/filings/0001628280-26-023008.md) | [163](/filings/0001628280-26-065423.md) | [143](/filings/0001628280-26-065423.md) |
| Total assets | $m | [500](/filings/0001628280-24-000857.md) | [325](/filings/0001628280-24-015487.md) | [318](/filings/0001275187-25-000014.md) | [294](/filings/0001628280-24-042176.md) | [292](/filings/0001275187-25-000005.md) | [285](/filings/0001275187-25-000010.md) | [280](/filings/0001628280-26-048138.md) | [266](/filings/0001628280-25-043689.md) | [270](/filings/0001275187-26-000003.md) | [261](/filings/0001628280-26-023008.md) | [267](/filings/0001628280-26-065423.md) | [242](/filings/0001628280-26-065423.md) |
| Current liabilities | $m | [78.0](/filings/0001628280-24-000857.md) | [85.9](/filings/0001628280-24-015487.md) | [91.2](/filings/0001275187-25-000014.md) | [76.7](/filings/0001628280-24-042176.md) | [88.6](/filings/0001275187-25-000005.md) | [78.0](/filings/0001275187-25-000010.md) | [76.2](/filings/0001628280-26-048138.md) | [68.3](/filings/0001628280-25-043689.md) | [72.0](/filings/0001275187-26-000003.md) | [66.1](/filings/0001628280-26-023008.md) | [74.7](/filings/0001628280-26-065423.md) | [59.7](/filings/0001628280-26-065423.md) |
| Total liabilities | $m | [98.4](/filings/0001628280-24-000857.md) | [106](/filings/0001628280-24-015487.md) | [112](/filings/0001275187-25-000014.md) | [97.0](/filings/0001628280-24-042176.md) | [105](/filings/0001275187-25-000005.md) | [99.5](/filings/0001275187-25-000010.md) | [97.2](/filings/0001628280-26-048138.md) | [86.8](/filings/0001628280-25-043689.md) | [93.3](/filings/0001275187-26-000003.md) | [87.3](/filings/0001628280-26-023008.md) | [96.3](/filings/0001628280-26-065423.md) | [78.0](/filings/0001628280-26-065423.md) |
| Long-term debt | $m | not reported | not reported | [0.0](/filings/0001628280-24-032989.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [401](/filings/0001275187-25-000010.md) | [219](/filings/0001275187-25-000010.md) | [206](/filings/0001628280-26-048138.md) | [197](/filings/0001628280-26-023008.md) | [187](/filings/0001628280-26-023008.md) | [186](/filings/0001628280-26-023008.md) | [183](/filings/0001628280-26-065423.md) | [179](/filings/0001628280-26-065423.md) | [176](/filings/0001628280-26-023008.md) | [173](/filings/0001628280-26-023008.md) | [171](/filings/0001628280-26-065423.md) | [164](/filings/0001628280-26-065423.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.3 d](/filings/0001275187-25-000005.md) | [(12.5) d](/filings/0001275187-25-000010.md) | [5.0 d](/filings/0001628280-26-048138.md) | [(18.3)](/filings/0001628280-25-043689.md) | [2.5 d](/filings/0001275187-26-000003.md) | [(13.2) d](/filings/0001628280-26-023008.md) | [18.8 d](/filings/0001628280-26-048138.md) | [(15.9)](/filings/0001628280-26-065423.md) | [4.7 d](/filings/0001275187-26-000003.md) | [(3.1) d](/filings/0001628280-26-023008.md) | [17.5 d](/filings/0001628280-26-048138.md) | [(15.3)](/filings/0001628280-26-065423.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001275187-25-000005.md) | [0.6 d](/filings/0001275187-25-000010.md) | [0.6 d](/filings/0001628280-26-048138.md) | [1.1](/filings/0001628280-25-043689.md) | [0.8 d](/filings/0001275187-26-000003.md) | [1.8 d](/filings/0001628280-26-023008.md) | [0.8 d](/filings/0001628280-26-048138.md) | [0.7](/filings/0001628280-26-065423.md) | [0.4 d](/filings/0001275187-26-000003.md) | [1.0 d](/filings/0001628280-26-023008.md) | [0.4 d](/filings/0001628280-26-048138.md) | [0.4](/filings/0001628280-26-065423.md) |
| Share repurchases | $m | [0.0 d](/filings/0001275187-25-000005.md) | [0.0 d](/filings/0001275187-25-000010.md) | [0.0 d](/filings/0001628280-26-048138.md) | [0.6](/filings/0001628280-25-043689.md) | [1.1 d](/filings/0001275187-26-000003.md) | [0.0 d](/filings/0001628280-26-023008.md) | [0.0 d](/filings/0001628280-26-048138.md) | [0.0](/filings/0001628280-25-043689.md) | [0.0 d](/filings/0001275187-26-000003.md) | [0.0 d](/filings/0001628280-26-023008.md) | [0.0 d](/filings/0001628280-26-048138.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.5](/filings/0001628280-24-000857.md) | [39.5](/filings/0001628280-24-015487.md) | [40.0](/filings/0001628280-24-042176.md) | [40.2](/filings/0001275187-25-000005.md) | [40.2](/filings/0001275187-25-000010.md) | [40.7](/filings/0001628280-25-043689.md) | [40.9](/filings/0001275187-26-000003.md) | [40.9](/filings/0001628280-26-023008.md) | [41.2](/filings/0001628280-26-065423.md) | [41.5](/filings/0001275187-26-000003.md) | [41.6](/filings/0001628280-26-023008.md) | [42.0](/filings/0001628280-26-065423.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,054,450 at 2026-10-07, from the cover of the [10-Q filed 2026-10-08](/filings/0001628280-26-065423.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.